Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic
David Gleeson, Juliet N. Barker, Francesca Capon, Andrew Pink, Richard Woolf, Catherine Smith, Satveer K. Mahil
Abstract
We carried out a critical appraisal of the literature to assess whether Janus kinase inhibitors are an effective treatment for palmoplantar pustulosis, a rare and debilitating form of psoraisis. Our appraisal identified case reports and case series of 16 patients who have been treated to good effect with tofacitinib, indicating this may be a promising therapeutic option. However, routine use of janus kinase inhibitors cannot be recommended outside the context of a clinical trial given the current low-quality of evidence available and the uncertain safety profile of Janus kinase inhibitors.
Topics & Concepts
Janus kinasePalmoplantar pustulosisTofacitinibMedicineCritical appraisalContext (archaeology)DermatologyJanus kinase inhibitorIntensive care medicinePsoriasisInternal medicinePathologyAlternative medicineBiologyPaleontologyRheumatoid arthritisCytokineAutoimmune Bullous Skin DiseasesPsoriasis: Treatment and PathogenesisDupuytren's Contracture and Treatments